Navigation Links
Tiny soft medicine factories

A factory built of gel does not sound very durable. But the new type of micro-factories invented by researchers at Aarhus University do not have to last.

They will actually be placed inside a patient's body exactly where the medicine is required and they will gradually dissolve and disappear in the patient's urine once their mission is accomplished.

The prospects are so enormous that Associate Professor of Chemistry Alexander Zelikin, Aarhus University, has just been granted EUR 2 million to boost research and development in this field. The European Research Council (ERC) has awarded him an ERC Consolidator Grant.

Very advanced gel

The tiny factories consist of hydrogel, which is fundamentally a mixture of water and polymers with characteristics similar to gelatine. In this case we deal with some advanced variants of hydrogels: They must simultaneously be able to function as material for the small factories and contain the enzymes needed to produce medicine while the raw material is arriving at the factories.

There is basically nothing new in allowing enzymes to be in charge of the medical production - plenty of drugs are made of inactive substances which are not converted into active drugs until the liver or enzymes elsewhere in the body begins to break them down. They are called prodrugs.

An ordinary prodrug is, for example acetylsalicylic acid, which is the main ingredient in the common types of pain-relieving drug. They will not work until your liver has converted them into alicylic acid.

"The problem with this type of prodrugs is, however, that after the conversion they are typically sent into the blood in the intire body, so that only a fraction reaches the place which hurts. This problem can be solved in the process by creating prodrugs, which can only be transformed by specific enzymes - and then placing these enzymes in th eparticular part of the body which needs the drugs," explains Alexander Zelikin.

He will spend the EUR 2 million on developing two types of biodegradable factories:

Stents and particles

One of them is a new kind of stent which, among other things, is a term for the small metal meshes, which is operated into patients suffering from blockage of their coronary artery to keep it open after an angioplasty.

Alexander Zelikin's stents will be made of hydrogel instead of metal, because their primary purpose is not to keep a vein open, but to deliver medicine: the doctor injects a prodrug into the patient's vein, after which the enzymes in the stent convert it to, for example, a medicine against arteriosclerosis.

"The same enzymes will also be able to transform other sorts of prodrugs, so if one medicine doesn't work, you can switch to another without having to call the patient in for a new treatment," says Alexander Zelikin and continues:

"Metal stents coated with medicine are already in use - they just do not have the flexibility, that treatment which the enzymatic medicine factories have."

The second sort will consist of small particles, which initially can be used for the treatment of diseases such as cancer. The particles must be able to submit both medicine and for example contrast agents, so that they can be used simultaneously for treatment and diagnosis.

More specifically, the ERC grant will result in the employment of four PhD students and a postdoc.

The technology is pending patent and is being commercialised through Technology Transfer Office at Aarhus University.

Contact: Alexander Zelikin
Aarhus University

Related biology news :

1. Price Family Foundation funds research collaboration between Albert Einstein College of Medicine and University of Oklahoma
2. In vitro innovation: Testing nanomedicine with blood cells on a microchip
3. Vitamin A used in acne medicines may help autoimmune and transplant patients
4. 2014 Louis-Jeantet Prize for Medicine
5. UD-developed smart gels deliver medicine on demand
6. NPL links up with GlaxoSmithKline to support research into new medicines
7. Traditional Chinese Medicine in Singapore is Now Available at Urbanrehab Pte Ltd
8. Plant used in Chinese medicine fights chronic pain
9. New hope for stem cells, regenerative medicine emerges from the lab
10. Timing is everything in new nanotechnology for medicine, security and research
11. CNIO study chosen as discovery of the year in regenerative medicine
Post Your Comments:
(Date:11/4/2015)... ALBANY, New York , November 4, 2015 /PRNewswire/ ... According to a new market report published by Transparency ... Size, Share, Growth, Trends and Forecast 2015 - 2022", ... value of US$ 30.3 bn by 2022. The market ... during the forecast period from 2015 to 2022. Rising ...
(Date:10/29/2015)... , Oct. 29, 2015  Rubicon Genomics, ... for U.S. distribution of its DNA library preparation ... and Rubicon,s new ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq ... the preparation of NGS libraries for liquid biopsies--the ... diagnostic and prognostic applications in cancer and other ...
(Date:10/27/2015)... , October 27, 2015 ... Automated Semantic Gaze Mapping technology (ASGM) automatically maps data ... Eye Tracking Glasses , so that they can ... --> Munich, Germany , October ... automatically maps data from mobile eye tracking videos created ...
Breaking Biology News(10 mins):
(Date:11/24/2015)... , Nov. 24, 2015  Clintrax Global, Inc., a worldwide ... Carolina , today announced that the company has set a ... a 391% quarter on quarter growth posted for Q3 of 2014 ... and Mexico , with the establishment of ... December 2015. --> United Kingdom and ...
(Date:11/24/2015)... 2015 --> ... released by Transparency Market Research, the global non-invasive prenatal ... of 17.5% during the period between 2014 and 2022. ... Industry Analysis, Size, Volume, Share, Growth, Trends and Forecast ... market to reach a valuation of US$2.38 bn by ...
(Date:11/24/2015)... Schlieren, Switzerland (PRWEB) , ... November 24, 2015 , ... ... more organotypic 3D cell culture models, has promoted Melanie Aregger to serve as Chief ... Manager, Ms. Aregger served on the management team and was promoted to ...
(Date:11/24/2015)...  PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI ) today ... and chief executive officer, will present at the 27 th ... New York City . The presentation will be ... at 9:30 a.m. EST. and go ... least 15 minutes prior to the presentation to allow for ...
Breaking Biology Technology: